Cargando…

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

BACKGROUND: Thymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome. METHODS: All patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kostopoulos, Ioannis, Karavasilis, Vasilios, Karina, Maria, Bobos, Mattheos, Xiros, Nikolaos, Pentheroudakis, George, Kafiri, Georgia, Papakostas, Pavlos, Vrettou, Eleni, Fountzilas, George
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759966/ https://www.ncbi.nlm.nih.gov/pubmed/19775480 http://dx.doi.org/10.1186/1471-2407-9-339

Ejemplares similares

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
por: Razis, Evangelia, et al.
Publicado: (2008)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

Genotyping data of routinely processed matched primary/metastatic tumor samples
por: Kotoula, Vassiliki, et al.
Publicado: (2020)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
por: Murray, Samuel, et al.
Publicado: (2012)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
por: Polychronidou, Genovefa, et al.
Publicado: (2018)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
por: Kourea, Helen P., et al.
Publicado: (2022)

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer
por: Ichikawa, W, et al.
Publicado: (2004)

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
por: Zarkavelis, George, et al.
Publicado: (2019)

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
por: Pentheroudakis, George, et al.
Publicado: (2015)

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)
por: Kotoula, Vassiliki, et al.
Publicado: (2012)

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018)

Effect of Hammerhead Ribozyme against Human Thymidylate Synthase on the Cytotoxicity of Thymidylate Synthase Inhibitors
por: Kobayashi, Hiroyuki, et al.
Publicado: (1995)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Trichinella pseudospiralis vs. T. spiralis thymidylate synthase gene structure and T. pseudospiralis thymidylate synthase retrogene sequence
por: Jagielska, Elżbieta, et al.
Publicado: (2014)

Protein expression patterns of cell cycle regulators in operable breast cancer
por: Zagouri, Flora, et al.
Publicado: (2017)

Conservation and Role of Electrostatics in Thymidylate Synthase
por: Garg, Divita, et al.
Publicado: (2015)

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study
por: Murray, Samuel, et al.
Publicado: (2010)

A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura
por: Hatzibougias, Dimitrios, et al.
Publicado: (2008)

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients
por: Krikelis, Dimitrios, et al.
Publicado: (2013)

Substrate Activation in Flavin-Dependent Thymidylate Synthase
por: Mishanina, Tatiana V., et al.
Publicado: (2014)

Concerted versus Stepwise Mechanism in Thymidylate Synthase
por: Islam, Zahidul, et al.
Publicado: (2014)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma
por: YOKOTA, KEISUKE, et al.
Publicado: (2012)

Analysis of mRNA recognition by human thymidylate synthase
por: Brunn, Nicholas D., et al.
Publicado: (2014)

Bacterial versus human thymidylate synthase: Kinetics and functionality
por: Islam, Zahidul, et al.
Publicado: (2018)

Dynamic allostery in substrate binding by human thymidylate synthase
por: Bonin, Jeffrey P, et al.
Publicado: (2022)

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
por: Chau, I, et al.
Publicado: (2004)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9c0figct3uaef6l8ltjsjq01pf